Kodiak Sciences (NASDAQ:KOD – Get Free Report)‘s stock had its “neutral” rating reaffirmed by HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $3.00 price target on the stock. HC Wainwright’s price objective would suggest a potential downside of 45.75% from the company’s previous close.
Kodiak Sciences Trading Up 4.3 %
Shares of NASDAQ KOD opened at $5.53 on Friday. Kodiak Sciences has a one year low of $1.89 and a one year high of $7.77. The business has a 50-day moving average price of $3.36 and a two-hundred day moving average price of $3.05. The firm has a market capitalization of $290.99 million, a PE ratio of -1.52 and a beta of 2.26.
Kodiak Sciences (NASDAQ:KOD – Get Free Report) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.01. Research analysts anticipate that Kodiak Sciences will post -3.52 EPS for the current year.
Institutional Investors Weigh In On Kodiak Sciences
About Kodiak Sciences
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Recommended Stories
- Five stocks we like better than Kodiak Sciences
- 3 Monster Growth Stocks to Buy Now
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Why Invest in High-Yield Dividend Stocks?
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- Following Congress Stock Trades
- Time to Load Up on Home Builders?
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.